TNFRSF8 and neoplasm: We developed a new ADC made of the small molecule zoledronic acid (ZA) and the therapeutic anti-CD30 antibody brentuximab–vedotin (Bre–Ved), able to strongly inhibit the proliferation of CD30+ HL/lymphoblastoid tumor cells.